The intelligent search engine for biomedical specialists

"GoPubMed is a sort of an intelligent Google for biomedical specialists," explains Dr Michael Alvers, CEO and Co-founder of Transinsight. "The search engine saves time and so accelerates research significantly."

Founded in November 2005, Transinsight is a software company focused on the life sciences that provides products and solutions for intelligent search technologies. Their main product, GoPubMed, was partly developed during the IST project, Biogrid, by Professor Michael Schroeder and his research team from the Biotechnology Centre at the Technical University of Dresden.

"Biomedical researchers have to be familiar with a huge number of publications," notes Schroeder, Transinsight's Chief Scientific Officer and Co-founder. "The PubMed database currently contains 15 million biomedical publications that have to be assessed by research groups."

"Researchers in the biotech and pharmaceutical industries spend an average of 12.4 hours a week searching for relevant information," adds Alvers.

GoPubMed can search literature repositories, websites, intranets and desktops. It indexes results and thus allows users to explore a large body of results in a structured manner.

In contrast to classical search engines, GoPubMed can answer questions using its background knowledge in molecular biology, medicine, drug development and food science. To illustrate this point, a search for 'aspirin inhibits' on a classical search engine returns a large number of unstructured results that do not answer the user's original question. On the other hand, a search with GoPubMed reveals that the most frequently mentioned pathway for 'aspirin inhibits' is the cyclooxygenase pathway.

Schroeder stresses, "GoPubMed] is intelligent and presents the search results in a way that is specifically linked to the interests of a particular research group."

Thanks to its groundbreaking and competitive product, the young company has already won its first corporate customer – Unilever in the UK. Explaining why Unilever decided to purchase the software, Dr Cecilia Eyre remarks "GoPubMed helps us to quickly screen the vast literature for hidden gems and to discover trends in science."

With exciting commercial prospects, the start-up company has also been quick to attract investment. This past January, it was announced that Transinsight had received €500,000 of seed funding from Germany's recently established High-Tech-Gründerfonds and a further undisclosed sum from a private investor in Hamburg.

Indeed, such are the high expectations for Transinsight, that the firm was very recently crowned as one of only three 'Lighthouse projects of the High-Tech-Gründerfonds' by Michael Glos, German Federal Minister for Economic Affairs and Technology.

Contact:
Dr Michael R. Alvers
CEO
Transinsight GmbH
Tatzberg 47-51
D-01307 Dresden
Germany
Tel: +49-351-46340059
Fax: +49-351-46340061
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Source: IST Results Portal

Most Popular Now

ChatGPT Extracts Data for Ischaemic Stro…

In an ischaemic stroke, an artery in the brain is blocked by blood clots and the brain cells can no longer be supplied with blood as a result. Doctors must...

Herefordshire and Worcestershire Health …

Herefordshire and Worcestershire Health and Care NHS Trust has successfully implemented Alcidion's Miya Precision platform to streamline bed management workflow across seven community hospitals in Worcestershire. The trust delivers community...

A Shortcut for Drug Discovery

For most human proteins, there are no small molecules known to bind them chemically (so called "ligands"). Ligands frequently represent important starting points for drug development but this knowledge gap...

New Horizon Europe Funding Boosts Europe…

The European Commission has announced the launch of new Horizon Europe calls, with a substantial funding pool of over €112 million. These calls are aimed primarily at pioneering projects in...

Cleveland Clinic Study Finds AI can Deve…

Cleveland Clinic researchers developed an artficial intelligence (AI) model that can determine the best combination and timeline to use when prescribing drugs to treat a bacterial infection, based solely on...

New AI-Technology Estimates Brain Age Us…

As people age, their brains do, too. But if a brain ages prematurely, there is potential for age-related diseases such as mild-cognitive impairment, dementia, or Parkinson's disease. If "brain age...

With Huge Patient Dataset, AI Accurately…

Scientists have designed a new artificial intelligence (AI) model that emulates randomized clinical trials at determining the treatment options most effective at preventing stroke in people with heart disease. The model...

Radboud University Medical Center and Ph…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Radboud University Medical Center have signed a hospital-wide, long-term strategic partnership that delivers the latest patient monitoring...

GPT-4, Google Gemini Fall Short in Breas…

Use of publicly available large language models (LLMs) resulted in changes in breast imaging reports classification that could have a negative effect on patient management, according to a new international...

ChatGPT fails at heart risk assessment

Despite ChatGPT's reported ability to pass medical exams, new research indicates it would be unwise to rely on it for some health assessments, such as whether a patient with chest...

Study Shows ChatGPT Failed when Challeng…

With artificial intelligence (AI) poised to become a fundamental part of clinical research and decision making, many still question the accuracy of ChatGPT, a sophisticated AI language model, to support...

Virtual Reality Shows Promise in Fightin…

A new study published in JMIR Mental Health sheds light on the promising role of virtual reality (VR) in treating major depressive disorder (MDD). Titled "Examining the Efficacy of Extended...